Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 6.2% – Should You Sell?

Posted by Geri Gentry on Jul 10th, 2026

Arbutus Biopharma Corporation (NASDAQ:ABUS – Get Free Report) shares traded down 6.2% during trading on Friday . The stock traded as low as $4.84 and last traded at $4.8230. Approximately 219,325 shares changed hands during trading, a decline of 90% from the average session volume of 2,125,152 shares. The stock had previously closed at $5.14.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ABUS. Weiss Ratings reissued a “sell (d-)” rating on shares of Arbutus Biopharma in a research note on Monday, April 20th. Wall Street Zen raised shares of Arbutus Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $5.00.

Read Our Latest Stock Analysis on ABUS

Arbutus Biopharma Stock Performance

The firm’s 50 day moving average price is $4.47 and its two-hundred day moving average price is $4.43. The company has a market cap of $927.45 million, a P/E ratio of 5.64 and a beta of 0.62.

Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) last issued its earnings results on Tuesday, March 31st. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter. The business had revenue of $179.13 million for the quarter. Arbutus Biopharma had a net margin of 83.95% and a return on equity of 129.32%. As a group, analysts forecast that Arbutus Biopharma Corporation will post -0.16 EPS for the current fiscal year.

Institutional Trading of Arbutus Biopharma

Several large investors have recently made changes to their positions in ABUS. Oxford Asset Management LLP bought a new stake in Arbutus Biopharma in the 2nd quarter valued at about $38,000. Voleon Capital Management LP bought a new position in Arbutus Biopharma in the third quarter worth approximately $47,000. Cibc World Markets Corp acquired a new stake in Arbutus Biopharma in the fourth quarter valued at approximately $48,000. Principal Financial Group Inc. acquired a new stake in Arbutus Biopharma in the first quarter valued at approximately $49,000. Finally, Daiwa Securities Group Inc. increased its holdings in shares of Arbutus Biopharma by 3,911.1% during the second quarter. Daiwa Securities Group Inc. now owns 15,844 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 15,449 shares in the last quarter. 43.79% of the stock is currently owned by institutional investors and hedge funds.

About Arbutus Biopharma

(Get Free Report)

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics.